Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Yoshiaki Takase (Gunma Pref., Japan), Yoshiaki Takase, Kimihiro Shimizu, Jun Atsumi, Yasuaki Enokida, Kai Obayashi, Yoichi Ohtaki, Toshiteru Nagashima, Tatsuo Ichihara, Yasumasa Kimura, Kengo Usui, Yasumasa Mitani, Izumi Takeyoshi. LATE-BREAKING ABSTRACT: Novel rapid screening assay for HER2 duplicated insertion mutation by Eprobe-PCR method. Eur Respir J 2015; 46: Suppl. 59, 4276

Member's Comments

No comment yet.

Related content which might interest you: Automated target-FISH lung cancer detection (LCD) test of induced sputum Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 The diagnostic puzzle of ALK rearrangement in lung cancer. A novel intron related abnormality Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Optimization of cfDNA routine use for NSCLC genomic alteration analysis Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in various types of clinical non-small cell lung cancer specimens Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 LATE-BREAKING ABSTRACT: EGFR specific single chain antibody deliver siRNAs restore gefitinib sensitivity in resistant NSCLC cells Source: International Congress 2014 – Thoracic tumours: news from the lab Year: 2014 The prognostic value of KRAS mutation according to the gene's Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 EGFR frequency and response to chemotherapy in a Brazilian NSCLC population Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Defining lineage relationships of multiple lung tumors through shared large genomic rearrangements Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome) Year: 2013 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014 Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015